Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Pharmaceutical Contract Win

14 Jan 2009 07:00

RNS Number : 5695L
Imaginatik PLC
14 January 2009
 



14 January 2009

Imaginatik Plc

("Imaginatik" or the "Company")

Pharmaceutical Contract Win

Imaginatik plc (AIM: IMTK), a leading provider of cost reduction, process improvement and collaborative innovation software and processes, is pleased to announce it has secured an annual contract with one of the world's leading pharmaceutical companies.

The annual contract, for 5,000 seats, is further evidence of the Company's strong presence within the pharmaceutical industry with the new client joining the likes of Pfizer, Merck, Novartis and Solvay on Imaginatik's client list. Imaginatik now provides its collaborative software to six of the world's top pharmaceutical companies, assisting those companies in harnessing the knowledge of their thousands of employees to identify potential new products, areas of cost-reduction and process enhancements. 

Under the terms of the contract, Imaginatik will be implementing its core product, Idea Central, across a number of divisions within the client, including Research, Prescription Medicine and IT. Idea Central will play a key role in delivering process and product improvement within these divisions.

A spokesperson for the client commented, "In furthering our emphasis on Value through Innovation, Imaginatik's Idea Central provided a focal point for idea generation and sharing, streamlined our reviewing process, and served as a vehicle for ongoing communication. We found Imaginatik's software and services to be particularly effective."

Mark Turrell, CEO of Imaginatik plc commented, "We are delighted to see the investment placed on strengthening our sales team being rewarded with significant annual contract wins which add to our increasingly impressive recurring revenue figure. This contract also once again demonstrates the value of our collaborative software to the pharmaceutical industry and we are confident that this will continue to be an excellent vertical for Imaginatik going forward."

For further information please contact:

Imaginatik plc

Tel: 020 7917 2975

Mark Turrell, CEO / Shawn Taylor, CFO

WH Ireland Limited

Tel: 0121 265 6330

Tim Cofman / Katy Birkin

ICIS

Tel: 020 7651 8688

Caroline Evans-Jones / Mike Smith

About Imaginatik

Imaginatik is the leading provider of cost reduction, process improvement and collaborative innovation software and processes to the world's leading companies. More than 100 clients rely on Imaginatik's software, consulting and research to enable their best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for the IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik's software and consulting services have helped clients discover significant sources of additional revenue, as well as tangible cost savings, process improvements and increased product pipeline. Imaginatik is also committed to developing strategic solutions in the field of innovation, working with academic institutions such as the London Business School and the Cass School of Business, London, as well as leading practitioners of corporate innovation.

For further information please visit www.imaginatik.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUOOVRKORAAAR
Date   Source Headline
15th Jun 20107:00 amRNSAppointment of Chief Operating Officer
1st Jun 20103:48 pmRNSHolding(s) in Company
13th May 20107:00 amRNSAppointment of Interim Vice President of Sales
6th May 20102:11 pmRNSHolding(s) in Company
28th Apr 20107:00 amRNSTrading Update
10th Mar 20107:00 amRNSDirector/PDMR Shareholding
4th Mar 20107:00 amRNSTrading Update
22nd Feb 20107:00 amRNSWindsor Foods Selects Imaginatik
17th Feb 20109:45 amRNSDirector Shareholding
29th Jan 201011:41 amRNSContract Win
22nd Dec 20097:00 amRNSDirectorate Change
17th Dec 20097:00 amRNSContract Win with Global Consumer Products Company
11th Dec 20097:00 amRNSContract Extension
17th Nov 20097:00 amRNSInterim Results
13th Nov 20097:00 amRNSContract Win
12th Nov 20097:00 amRNSNotice of Results
9th Oct 20097:00 amRNSTrading Update & Directorate Change
2nd Oct 20097:00 amRNSContract Win with global technology business
28th Sep 20097:00 amRNSContract Win with US Insurer
24th Sep 20097:00 amRNSDirector/PDMR Shareholding
23rd Sep 20097:00 amRNSProduct Launch
10th Sep 20097:00 amRNSContract Win
8th Sep 20097:00 amRNSWorld Economic Forum
13th Aug 20094:26 pmRNSHolding(s) in Company
13th Aug 20093:00 pmRNSHolding(s) in Company
13th Aug 200911:18 amRNSDirector/PDMR Shareholding
12th Aug 20095:17 pmRNSAdditional Listing
10th Aug 20097:00 amRNSPlacing
28th Jul 20097:00 amRNSAGM Statement
3rd Jul 20092:21 pmRNSDirector/PDMR - Share Subscription
29th Jun 20092:34 pmRNSAnnual Report & Accounts
17th Jun 20097:00 amRNSFinal Results
2nd Jun 20097:00 amRNSChange of Adviser & Notice of Results
15th May 200910:33 amRNSDirectorate Change
3rd Apr 20097:00 amRNSContract Win & Trading Update
19th Mar 20097:00 amRNSContract Extension with Chubb
5th Feb 20097:00 amRNSManagement Appointment
23rd Jan 20094:30 pmRNSDirector/PDMR Shareholding
23rd Jan 20097:00 amRNSWorld Economic Forum
15th Jan 20097:00 amRNSTrading on PLUS
14th Jan 20093:10 pmRNSDirector/PDMR Shareholding
14th Jan 20097:00 amRNSPharmaceutical Contract Win
9th Jan 20099:09 amRNSDirector/PDMR Shareholding
7th Jan 20091:35 pmRNSDirector/PDMR Shareholding
5th Jan 200911:10 amRNSDirector/PDMR Shareholding
5th Jan 20099:40 amRNSDirector/PDMR Shareholding
2nd Jan 20099:05 amRNSDirector/PDMR Shareholding
31st Dec 20087:00 amRNSDirector/PDMR Shareholding
31st Dec 20087:00 amRNSTotal Voting Rights
24th Dec 200810:48 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.